Moderna, a US pharmaceutical company, has announced the development of a single-dose vaccination option that combines a Covid-19 booster with a seasonal flu vaccine.
“We believe our mRNA platform can tackle the world’s largest health concerns,” said CEO Stephane Bancel, “from diseases that affect millions to ultra-rare diseases that affect hundreds to medicines that are personalized down to the individual level.”
“Today, we’re announcing the first step in our new respiratory vaccination initiative, with the development of a single-dose vaccine that includes a Covid-19 and flu booster,” she continued.
The Covid-19 spike protein and flu hemagglutinin glycoproteins are encoded by the combination vaccine mRNA-1073.
Vaccinations against viral diseases are being developed by Moderna, including vaccines against acute respiratory infections, vaccines against persistent infections, and vaccines against global public health risks.
“We are making progress in enrolling patients in our rare illness programmes, and our customized cancer vaccination trial is now completely enrolled. We feel we are only at the start of a new era of information-based medicine “Bancel remarked.
The US pharmaceutical company applied to the US Food and Drug Administration (FDA) last week to have a booster dose of its mRNA-based Covid-19 vaccine reviewed.
Early experiments showed that the 50-microgram dose level of mRNA-1273 booster injection generated significant antibody responses of more than 40 times against the highly infectious Delta variant (B.1.617.2), according to the organization.
In December 2020, the US regulatory board has approved the emergency use of Moderna’s Covid-19 vaccine for anyone aged 18 and up. It has got emergency approval from health officials in more than 50 nations to deploy its Covid-19 vaccination in adults.
Moderna Covid-19 is an mRNA vaccine that protects against Covid-19, which codes for a prefusion stabilized version of the Spike (S) protein.